Clinical features and results of surgical treatment of bilateral renal cancer
https://doi.org/10.17650/1726-9776-2018-14-1-47-56
Abstract
Renal cancer morbidity grows in most of the developed countries. Incidence of bilateral renal cell carcinoma, per various authors, amounts to 2–6 % of all cases of this disease. The study included 160 patients with bilateral kidney cancer who received surgical treatment at the N.N. Blokhin National Medical Research Center of Oncology in the period from 1996 to 2014. Median follow-up duration for all patients included in the analysis was 81.05 ± 46.7 months. In our study, the groups for synchronous and metachronous cancer were equal (n = 80) and constituted 3.5 % of all cases of kidney cancer. For synchronous and metachronous cancer types, the most common concomitant disease was arterial hypertension. The most common morphological variant for the first, as well as the second, kidney tumor was clear cell carcinoma. Smoking and ischemic heart disease as a concomitant pathology negatively affected relapse-free and overall survival. Overall 5-year survival for synchronous renal cancer was 84.4 ± 4.2 %, for metachronous – 64.8 ± 9.3 %.
About the Authors
M. I. Komarov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: нет конфликта интересов
V. B. Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: нет конфликта интересов
L. G. Zhukova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: нет конфликта интересов
I. G. Komarov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: нет конфликта интересов
V. A. Chernyaev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: нет конфликта интересов
References
1. Malignant neoplasm statistics in Russia and CIS countries in 2012. Eds.: E.M. Aksel’, M.I. Davydov. Moscow: Izdatelskaya gruppa RONC im. N.N. Blokhina RAMN, 2014. (In Russ.).
2. Malignant tumors in Russia in 2016 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2018. 250 p. (In Russ.).
3. Ferlay J., Steliarova-Foucher E., LortetTieulent J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374–403. DOI: 10.1016/j.ejca.2012.12.027. PMID: 23485231.
4. United States Renal Data System. 2007 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), U.S. Department of Health and Human Services (DHHS). Bethesda, MD, 2007.
5. Kel’n A.A., Lykov A.V., Kupchin A.V. Bilateral renal cell carcinoma. Tyumenskiy meditsinskiy zhurnal = Tyumen Medical Journal 2015;17(1):46–8. (In Russ.).
6. Davydov M.I., Matveev V.B. Surgical treatment of regional and metastatic renal cancer. Moscow: Izdatelskaya gruppa RONC im. N.N. Blokhina RAMN, 2002. (In Russ.).
7. Pereverzev A.S., Shchukin D.V., Ilyu- khin Yu.A. et al. Surgical treatment of bilateral renal cell carcinoma. Urologiya = Urology 2003;(2):7–12. (In Russ.).
8. Klatte T., Wunderlich H., Patard J.J. et al. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int 2007;100(1):21–5. DOI: 10.1111/j.1464-410X.2007.06877.x. PMID: 17433034.
9. Bratslavsky G., Linehan W.M. Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat Rev Urol 2010;7(5):267–75. DOI: 10.1038/nrurol.2010.44. PMID: 20448660.
10. Matveev V.B., Volkova M.I. Guidelines of the European Association of Urology on renal cancer treatment. Onkourologiya = Cancer Urology 2008;(1):21–4. (In Russ.).
11. Komyakov B.K., Zamyatin S.A., Narimanyan Z.N. et al. Surgical treatment of patients with regional and disseminated renal cell carcinoma. Vrach-aspirant = Postgraduate Doctor 2012;52(3.3):403–8. (In Russ.).
12. Cheng L., Zhang S., MacLennan G.T. et al. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 2009;40(1):10–29. DOI: 10.1016/j.humpath.2008.09.009. PMID: 19027455.
13. Аляев Ю.Г., Григорян З.Г. Двусторонний рак почек. Онкоурология 2008;(3):16–23. [Alyaev Yu.G., Grigo- ryan Z.G. Bilateral renal cancer. Onkourologiya = Cancer Urology 2008;(3):16–23. (In Russ.)].
14. Bratslavsky G., Liu J.J., Johnson A.D. et al. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol 2008;179(1):67–70. DOI: 10.1016/j.juro.2007.08.150. PMID: 17997447.
Review
For citations:
Komarov M.I., Matveev V.B., Zhukova L.G., Komarov I.G., Chernyaev V.A. Clinical features and results of surgical treatment of bilateral renal cancer. Cancer Urology. 2018;14(1):47-56. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-1-47-56
Views:
977
Email this article 